Insider Trading › ATHA › Insiders
ATHA
ATHA·Insider activity
—
No end-of-day price on record
ATHA
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ATHAS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
No open-market insider purchases or sales of ATHA were filed in the last 180 days. Newest filing Jan 5, 2026 (9 months ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by ATHA insiders · Form 4 · last two years
On Record
$0Purchases · 180 days
$0Sales · 180 days
64Open-market transactions on record
0Insiders filing · 180 days
Purchases (code P) and sales (code S) of ATHA common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
64 on record · newest trade first
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| Renninger RobertChief Financial Officer | Sale | −297 | $6.88 | $2K | 12.9Kdirect | Jan 2, 2026 | Jan 5, 2026 | Form 4 ↗ |
| Worthington MarkGeneral Counsel and CCO | Sale | −876 | $6.88 | $6K | 14.0Kdirect | Jan 2, 2026 | Jan 5, 2026 | Form 4 ↗ |
| CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Sale | −876 | $6.88 | $6K | 20.7Kdirect | Jan 2, 2026 | Jan 5, 2026 | Form 4 ↗ |
| San Martin JavierCHIEF MEDICAL OFFICER | Sale | −1,644 | $6.88 | $11K | 10.2Kdirect | Jan 2, 2026 | Jan 5, 2026 | Form 4 ↗ |
| Litton Mark JamesPresident and CEO · Director | Sale | −2,586 | $6.88 | $18K | 40.8Kdirect | Jan 2, 2026 | Jan 5, 2026 | Form 4 ↗ |
| CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Sale | −8,526 | $0.29 | $2K | 168.9Kdirect | Jul 1, 2025 | Jul 2, 2025 | Form 4 ↗ |
| Litton Mark JamesPresident and CEO · Director | Sale | −25.1K | $0.29 | $7K | 325.8Kdirect | Jul 1, 2025 | Jul 2, 2025 | Form 4 ↗ |
| San Martin JavierCHIEF MEDICAL OFFICER | Sale | −10.8K | $0.29 | $3K | 71.7Kdirect | Jul 1, 2025 | Jul 2, 2025 | Form 4 ↗ |
| Worthington MarkGeneral Counsel and CCO | Sale | −8,526 | $0.29 | $2K | 111.9Kdirect | Jul 1, 2025 | Jul 2, 2025 | Form 4 ↗ |
| Renninger RobertSVP, Finance and Accounting | Sale | −2,897 | $0.29 | $840 | 109.2Kdirect | Jul 1, 2025 | Jul 2, 2025 | Form 4 ↗ |
| San Martin JavierCHIEF MEDICAL OFFICER | Sale | −10.8K | $0.56 | $6K | 35.8Kdirect | Jan 2, 2025 | Jan 3, 2025 | Form 4 ↗ |
| Litton Mark JamesPresident and CEO · Director | Sale | −25.1K | $0.56 | $14K | 242.6Kdirect | Jan 2, 2025 | Jan 3, 2025 | Form 4 ↗ |
| CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Sale | −8,510 | $0.56 | $5K | 130.8Kdirect | Jan 2, 2025 | Jan 3, 2025 | Form 4 ↗ |
| Renninger RobertVP of Finance | Sale | −2,881 | $0.56 | $2K | 89.7Kdirect | Jan 2, 2025 | Jan 3, 2025 | Form 4 ↗ |
| Worthington MarkGeneral Counsel and CCO | Sale | −8,510 | $0.56 | $5K | 83.7Kdirect | Jan 2, 2025 | Jan 3, 2025 | Form 4 ↗ |
| Gengos AndrewCFO and Chief Business Officer | Sale | −1,272 | $0.57 | $725 | 97.5Kdirect | Sep 5, 2024 | Sep 5, 2024 | Form 4 ↗ |
| Lenington RachelCOO and CDO | Sale | −2,525 | $0.57 | $1K | 20.9Kdirect | Sep 5, 2024 | Sep 5, 2024 | Form 4 ↗ |
| CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Sale | −2,525 | $0.57 | $1K | 92.7Kdirect | Sep 5, 2024 | Sep 5, 2024 | Form 4 ↗ |
| Worthington MarkGENERAL COUNSEL | Sale | −2,525 | $0.57 | $1K | 51.9Kdirect | Sep 5, 2024 | Sep 5, 2024 | Form 4 ↗ |
| Litton Mark JamesPresident and CEO · Director | Sale | −5,032 | $0.57 | $3K | 159.4Kdirect | Sep 5, 2024 | Sep 5, 2024 | Form 4 ↗ |
| Romano Kelly ADirector | Purchase | +27.4K | $2.42 | $66K | 80.7Kdirect | Jun 24, 2024 | Jun 25, 2024 | Form 4 ↗ |
| Romano Kelly ADirector | Purchase | +15.0K | $2.26 | $34K | 53.3Kdirect | Jun 21, 2024 | Jun 25, 2024 | Form 4 ↗ |
| Lenington RachelCOO AND CDO | Sale Amended | −2,412 | $2.91 | $7K | 13.4Kdirect | Jan 5, 2024 | Feb 16, 2024 | Form 4 ↗ |
| Litton Mark JamesCEO · Director | Sale Amended | −4,820 | $2.91 | $14K | 144.4Kdirect | Jan 5, 2024 | Feb 16, 2024 | Form 4 ↗ |
| Worthington MarkGENERAL COUNSEL | Sale Amended | −2,412 | $2.91 | $7K | 34.5Kdirect | Jan 5, 2024 | Feb 16, 2024 | Form 4 ↗ |
| Gengos AndrewCFO AND CHIEF BUSINESS OFFICER | Sale Amended | −1,208 | $2.91 | $4K | 83.8Kdirect | Jan 5, 2024 | Feb 16, 2024 | Form 4 ↗ |
| CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Sale Amended | −2,412 | $2.91 | $7K | 80.3Kdirect | Jan 5, 2024 | Feb 16, 2024 | Form 4 ↗ |
| Litton Mark JamesChief Executive Officer · Director | Sale | −4,820 | $2.91 | $14K | 144.4Kdirect | Jan 5, 2024 | Jan 8, 2024 | Form 4 ↗ |
| Worthington MarkGeneral Counsel | Sale | −2,412 | $2.91 | $7K | 34.5Kdirect | Jan 5, 2024 | Jan 8, 2024 | Form 4 ↗ |
| Lenington RachelChief Operating Officer | Sale | −2,412 | $2.91 | $7K | 13.4Kdirect | Jan 5, 2024 | Jan 8, 2024 | Form 4 ↗ |
| EDELMAN JOSEPHDirector · 10% owner | Purchase | +164.0K | $2.38 | $390K | 5.4Mindirect | Dec 29, 2023 | Dec 29, 2023 | Form 4 ↗ |
| EDELMAN JOSEPHDirector · 10% owner | Purchase | +409.6K | $2.44 | $999K | 5.2Mindirect | Dec 28, 2023 | Dec 29, 2023 | Form 4 ↗ |
| EDELMAN JOSEPHDirector · 10% owner | Purchase | +32.1K | $2.28 | $73K | 4.8Mindirect | Dec 27, 2023 | Dec 29, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +11.7K | $3.44 | $40K | 80.0Kdirect | Jun 7, 2023 | Jun 9, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +2,859 | $3.40 | $10K | 68.3Kdirect | Jun 7, 2023 | Jun 9, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +422 | $3.36 | $1K | 65.4Kdirect | Jun 7, 2023 | Jun 9, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +10.0K | $3.02 | $30K | 65.0Kdirect | Jun 5, 2023 | Jun 6, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +10.0K | $3.00 | $30K | 55.0Kdirect | Jun 5, 2023 | Jun 6, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +10.0K | $3.00 | $30K | 45.0Kdirect | Jun 5, 2023 | Jun 6, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +15.0K | $3.00 | $45K | 35.0Kdirect | Jun 5, 2023 | Jun 6, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +3,418 | $2.95 | $10K | 20.0Kdirect | Jun 2, 2023 | Jun 6, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +6,582 | $2.86 | $19K | 16.6Kdirect | Jun 2, 2023 | Jun 6, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Purchase | +10.0K | $2.75 | $28K | 10.0Kdirect | Jun 2, 2023 | Jun 6, 2023 | Form 4 ↗ |
| PICKERING GRANTDirector | Purchase | +15.0K | $2.47 | $37K | 25.8Kdirect | Mar 30, 2023 | Mar 31, 2023 | Form 4 ↗ |
| PICKERING GRANTDirector | Purchase | +10.0K | $2.33 | $23K | 10.8Kdirect | Mar 29, 2023 | Mar 31, 2023 | Form 4 ↗ |
| JOHNSON JAMES ADirector | Purchase | +5,000 | $2.40 | $12K | 5,000direct | Mar 29, 2023 | Mar 30, 2023 | Form 4 ↗ |
| Gengos AndrewSee Below | Sale | −1,208 | $2.91 | $4K | 83.8Kdirect | Jan 5, 2023 | Jan 8, 2024 | Form 4 ↗ |
| CHURCH KEVINChief Scientific Officer | Sale | −2,412 | $2.91 | $7K | 80.3Kdirect | Jan 5, 2023 | Jan 8, 2024 | Form 4 ↗ |
| MILESON GLENNAChief Financial Officer | Purchase | +50.0K | $2.85 | $143K | 159.9Kdirect | Dec 28, 2022 | Dec 30, 2022 | Form 4 ↗ |
| Romano Kelly ADirector | Purchase | +30.0K | $3.29 | $99K | 38.3Kdirect | Dec 2, 2022 | Dec 6, 2022 | Form 4 ↗ |
| MOEBIUS HANSChief Medical Officer | Purchase | +5,000 | $3.29 | $16K | 65.8Kdirect | Nov 15, 2022 | Nov 17, 2022 | Form 4 ↗ |
| EDELMAN JOSEPHDirector · 10% owner | Purchase | +1.1M | $2.99 | $3.3M | 4.8Mindirect | Jun 30, 2022 | Jul 1, 2022 | Form 4 ↗ |
| EDELMAN JOSEPHDirector · 10% owner | Purchase | +270.0K | $2.99 | $807K | 3.7Mindirect | Jun 29, 2022 | Jul 1, 2022 | Form 4 ↗ |
| MOEBIUS HANSChief Medical Officer | Purchase | +10.0K | $2.88 | $29K | 53.0Kdirect | Jun 28, 2022 | Jun 30, 2022 | Form 4 ↗ |
| Worthington MarkGeneral Counsel | Sale | −2,614 | $2.69 | $7K | 19.1Kdirect | Jun 23, 2022 | Jun 24, 2022 | Form 4 ↗ |
| MILESON GLENNAChief Financial Officer | Sale | −2,614 | $2.69 | $7K | 109.2Kdirect | Jun 23, 2022 | Jun 24, 2022 | Form 4 ↗ |
| Litton Mark JamesChief Executive Officer · Director | Sale | −7,960 | $2.69 | $21K | 128.6Kdirect | Jun 23, 2022 | Jun 24, 2022 | Form 4 ↗ |
| Lenington RachelChief Operating Officer | Sale | −4,193 | $2.69 | $11K | 5,807direct | Jun 23, 2022 | Jun 24, 2022 | Form 4 ↗ |
| CHURCH KEVINExecutive VP, Research | Sale | −2,614 | $2.69 | $7K | 57.7Kdirect | Jun 23, 2022 | Jun 24, 2022 | Form 4 ↗ |
| Romano Kelly ADirector | Purchase | +8,000 | $13.11 | $105K | 8,315direct | Mar 31, 2022 | Apr 1, 2022 | Form 4 ↗ |
| EDELMAN JOSEPHDirector · 10% owner | Purchase | +311.1K | $22.50 | $7.0M | 3.4Mindirect | Jan 25, 2021 | Jan 27, 2021 | Form 4 ↗ |
| EDELMAN JOSEPHDirector · 10% owner | Purchase | +1.1M | $17.00 | $18.0M | 3.1Mindirect | Sep 22, 2020 | Sep 22, 2020 | Form 4 ↗ |
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD10% owner | Purchase | +1.1M | $17.00 | $18.0M | 3.1Mindirect | Sep 22, 2020 | Sep 22, 2020 | Form 4 ↗ |
| RTW INVESTMENTS, LP10% owner | Purchase | +750.0K | $17.00 | $12.8M | 2.7Mindirect | Sep 18, 2020 | Sep 22, 2020 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →